期刊文献+

胃癌根治术联合多西他赛及卡培他滨治疗进展期胃癌临床观察 预览

Clinical Observation on Radical Gastrectomy Combined with Docetaxel and Capecitabine in the Treatment of Advanced Gastric Cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨胃癌根治术联合多西他赛及卡培他滨治疗进展期胃癌的临床疗效。方法选取医院2014年1月至2016年1月收治的胃癌根治术后进展期胃癌患者76例,按随机数字表法分为对照组和观察组,各38例。对照组患者采用多西他赛、奥沙利铂及5-氟尿嘧啶/醛氢叶酸进行化学治疗(简称化疗),观察组患者采用多西他赛和卡培他滨进行化疗同步放射治疗(简称放疗)。结果观察组患者近期有效率为92.11%,显著高于对照组的71.05%(P<0.05);观察组治疗后1年胃肠功能评分、1年生存率、3年生存率均显著高于对照组(P<0.05);观察组患者治疗后1年和3年卡氏生活质量评分均显著高于对照组(P<0.05);观察组与对照组不良反应发生率相当(42.11%比55.26%,P>0.05)。结论胃癌根治术联合多西他赛及卡培他滨治疗进展期胃癌,均有一定近期及远期疗效,且可改善患者的生活质量。 Objective To investigate the clinical efficacy of radical gastrectomy combined with docetaxel and capecitabine in the treatment of advanced gastric cancer.Methods Totally 76 patients with advanced gastric cancer treated with radical gastrectomy admitted to our hospital from January 2014 to January 2016 were selected and divided into the control group and the observation group according to the random number table method,38 cases in each group.The patients in the control group were treated with docetaxel,oxaliplatin,and 5-fluorouracil/aldosterone for chemotherapy,while the patients in the observation group were treated with docetaxel combined with capecitabine for chemotherapy and radiotherapy.Results The short-term effective rate of the observation group was 92.11%,which was significantly higher than 71.05%of the control group(P<0.05).The gastrointestinal function score after 1 year of treatment,1-year survival rate and 3-year survival rate in the observation group were significantly higher than those in the control group(P<0.05).One and three years after treatment,the KPS scores in the observation group were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(42.11%vs.55.26%,P>0.05).Conclusion Radical gastrectomy combined with docetaxel and capecitabine has certain short-term and long-term effects in the treatment of advanced gastric cancer,which can improve the quality of life of patients.
作者 张振毫 钱莉 ZHANG Zhenhao;QIAN Li(Ezhou Iron and Steel Hospital,Ezhou,Hubei,China 436000;Hanchuan People's Hospital,Xiaogan,Hubei,China 432300)
出处 《中国药业》 CAS 2019年第22期49-51,共3页 China Pharmaceuticals
基金 湖北省自然科学基金[EK2016D200062001658]。
关键词 胃癌根治术 多西他赛 卡培他滨 进展期胃癌 临床疗效 radical gastrectomy docetaxel capecitabine advanced gastric cancer clinical efficacy
作者简介 第一作者:张振毫,男,大学本科,主治医师,研究方向为胃癌的治疗,电子信箱:904232464@qq.com。
  • 相关文献
投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏